Hemophagocytic Lymphohistiocytosis in Adults: Low Incidence of Primary Neoplasm as a Trigger in a Case Series from Turkey

Ferhat Arslan1, Sehnaz Alp2, Yahya Büyükasık3, Melda Comert Ozkan4, Fahri Şahin4, Seniha Basaran5, Arif Atahan Cagatay6, Ömer Haluk Eraksoy5, Kenan Aksu6, Barış Ertunç7, Volkan Korten8, Bahadır Ceylan9 and Ali Mert9.

1 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
2 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
3 Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
4 Department of Hematology, Faculty of Medicine, Ege University, İzmir, Turkey.
5 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
6 Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Ege University, İzmir, Turkey.
7 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
8 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Marmara University, İstanbul, Turkey.
9 Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, İstanbul Medipol University, İstanbul, Turkey.

Competing interests: The authors have declared that no competing interests exist.

Abstract. Hemophagocytic Lymphohistiocytosis (HLH) is an indicator of an exaggerated immune response and eventually adverse outcomes. This study aimed to investigate the clinical and laboratory features and outcomes of patients with HLH. The medical records of 26 HLH adult patients (≥ 16 years of age) were retrospectively analyzed. Gender, age, the duration of fever, time to diagnosis, etiology and laboratory data were extracted from the records. The mean age was 38 ± 18 years, and 15 (58%) patients were female. A total of nine cases had infectious diseases; four cases had rheumatologic diseases, three cases had hematological malignancies while nine cases could not have a definitive diagnosis. The median time to detection of HLH was 20 days (IQR: 8-30 d). Of the 25 patients, 11 (44%) died. The erythrocyte sedimentation rates of the surviving and non-surviving patients were 39 ± 22 mm/h and 15 ± 13 mm/h, respectively. When a long-lasting fever is complicated by bicytopenia or pancytopenia (especially), clinicians should promptly consider the possibility of HLH syndrome to improve patients’ prognosis.

Keywords: Hemophagocytic lymphohistiocytosis, Ferritin, Cytopenia, Fever of unknown origin.

Citation: Arslan F., Alp S., Büyükasık Y., Ozkan M.C., Şahin F., Basaran S., Cagatay A.A., Eraksoy Ö.H., Aksu K., Ertunç B., Korten V., Ceylan B., Mert A. Hemophagocytic lymphohistiocytosis in adults: low incidence of primary neoplasm as a trigger in a case series from Turkey. Mediterr J Hematol Infect Dis 2018, 10(1): e2018047, DOI: http://dx.doi.org/10.4084/MJHID.2018.047

Published: September 1, 2018  Received: February 22, 2018  Accepted: July 11, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Ferhat Arslan, MD. Department of Infectious Diseases and Clinical Microbiology, İstanbul Medeniyet University Hospital, İstanbul, Turkey. Tel.: +90 505 580 22 45. E-mail: ferhatarslandr@hotmail.com
Introduction. Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening clinical condition caused by an exaggerated immune response that results in tissue destruction. Its primary form generally occurs due to an underlying genetic immune dysfunction and primarily affects infants and young children, whereas the secondary form occurs due to various underlying conditions ranging from viral infections to autoimmune diseases and cancers in adults.

The clinical features of HLH include fever, hepatosplenomegaly, lymphadenopathy, neurological symptoms, and skin manifestations. Cytopenia, elevated liver enzymes, high serum ferritin levels, hypertriglyceridemia, and hypofibrinogenemia are laboratory abnormalities that have frequently been reported in HLH patients. Although extremely elevated ferritin levels represent a highly sensitive marker of HLH, this disease may be difficult to recognize and diagnose. Early diagnosis and prompt treatment of the underlying cause are important to decrease morbidity and mortality in patients with HLH. In this study, we aimed to investigate the clinical features and outcomes of patients with HLH in tertiary care centers in Turkey through a retrospective chart review.

Materials and Methods. The medical records of adult patients (≥ 16 years of age) diagnosed with HLH between January 2010 and April 2016 at six university hospitals in Turkey were reviewed retrospectively. Infectious disease, rheumatology, and hematology specialists were contacted for the records. The Istanbul Medipol University Ethical Committee approved this study.

All the patients who met the diagnostic guidelines of the Histiocyte Society (HLH-2004) were included in this study (Table 1). Molecular parameters, such as NK cell activity and soluble CD25, were not available in this study due to a lack of laboratory facilities. The following features were evaluated: fever (type, duration), time to diagnosis, splenomegaly, hepatomegaly, lymphadenopathy, rash, serosal involvement, respiratory symptoms, neurological symptoms, and opportunistic infections. Hemophagocytosis and splenomegaly were defined as the long axis of the organs exceeding 155 mm and 130 mm on radiological investigations, respectively.

Table 1. Hemophagocytic Lymphohistiocytosis 2004 Trial Diagnostic and Modified Criteria.

| HLH 2004 criteria | Fever ≥ 38.5°C |
|-------------------|---------------|
|                   | Splenomegaly  |
|                   | Cytopenia (at least two of the following): |
|                   | - Hemoglobin < 9 g/dL |
|                   | - Platelets < 100,000/µL |
|                   | - ANC < 1,000/µL |
|                   | Triglycerides > 265 mg/dL and/or fibrinogen < 150 mg/dL |
|                   | Ferritin > 500 ng/mL |
|                   | Hemophagocytosis (bone marrow, spleen, lymph node, or liver) |
|                   | Low or absent NK cell activity |
|                   | Elevated soluble CD25 (soluble IL-2 receptor alpha) |

ANC, absolute neutrophil count; NK, natural killer, IL-2, interleukin 2. Measurements of the underlined, italicized markers were not available in this study.

Hemogram, ferritin, lactate dehydrogenase (LDH), transaminase, bilirubin, triglyceride, high-density lipoprotein (HDL), and fibrinogen levels and erythrocyte sedimentation rates (ESRs) were analyzed. Hemophagocytosis was defined as histological evidence of activated macrophages engulfing blood cells in the bone marrow and/or other tissues.

Opportunistic infections were defined as a new clinical condition with ongoing immunosuppression due to HLH. When positron emission tomography with computed tomography (PET/CT) was performed, the presence of fluorodeoxyglucose (FDG) uptake was evaluated. Underlying triggering diseases and treatment modalities, including types of initial therapy, secondary therapy, and adjunctive therapy (supportive or underlying disease-specific treatment), were evaluated. Patients without both ferritin and triglyceride levels in their medical records were excluded.

The basic statistical analysis was performed using R version 3.0.4. Results are expressed as numbers (percentages) for categoric variable and as mean (standard deviation) or median (interquartile range) for continuous variables. The chi-square test and contingency table were used to compare subgroups of patients. p values of less than 0.05 were considered as statistically significant.

Results. 26 patients met the inclusion criteria. The mean age of the patients was 38 years (range, 16-74), and 15 (58%) females were included. The triggering etiologies were established in 17 cases (65%) and were as follows: infection in 9 cases...
Bone marrow biopsy showed hemophagocytosis in 22 of 26 (84%) patients. Additionally, there was bone marrow involvement in two of the lymphoma cases. Activated macrophages with maturation arrest (in 2 patients) and chronic lymphoproliferation were the other findings in bone marrow biopsies. Hemophagocytosis and hemosiderosis were observed in liver biopsies of two of these patients.

Of the 26 patients, eight were evaluated by PET/CT scans; their findings are summarized in Table 2.

All the patients with HLH received specific treatment for the hemophagocytic syndrome. Three patients (12%) were treated only with glucocorticoids, whereas the others received both glucocorticoids and another drug(s) as initial treatment. The underlying diseases, HLH-associated laboratory values and initial, secondary, and adjunctive treatment modalities of the patients after HLH diagnosis are summarized in Table 2.

Discussion. Various underlying conditions that predispose patients to HLH have been defined in previous studies. In children, underlying genetic defects play a predominant part in the development of HLH. Although malignancies, frequently hematologic, seem to be the leading cause of adult-onset HLH, the predominant cause of HLH may differ by country because of different genetic/ethnic backgrounds or differences in triggering agents, particularly infections. However, only 3 of 26 patients in our study were diagnosed with lymphoma. Although, this finding may reflect the underrepresentation of hematology units at participating centers or underdiagnosed lymphoproliferative diseases, a similar distribution of causes of this disease in the Mediterranean Region has been found in Spain but not in Italy and in France.

Many clinical and laboratory features were consistent with those reported previously, e.g., high fever, cytopenia, splenomegaly, hepatomegaly, and hyperferritinemia. Fever was the primary presenting symptom in all of our patients, which is similar to a report from Riviere et al. Hyperferritinemia is a sensitive marker of HLH. No cutoff value has been defined as critical; however, high levels of ferritin (> 50,000 µg/L) are associated with a poor prognosis. Hypofibrinogenemia is the main factor for blood
cells velocity that also stated as bad prognostic factor for HLH. Riviere et al. found higher LDH and total bilirubin levels in non-survivors higher than those of the survivors. But, due to limited numbers of patients to conclude statistical significance with parametric and non-parametric tests, we do not give any hypothetical test results here. We may say that more tissue destruction like liver as cholestatic hepatitis and blood cells hemolysis can explain the higher LDH and total bilirubin levels in non-survivors as bad prognostic factors.

Neurological symptoms may manifest as different clinical presentations, ranging from depression and convulsions to progressive encephalopathy. In one study, HSV reactivation was not found in patients with hemophagocytosis and multi-organ failure. In contrast, two of the five cases with neurological findings in our study resulted in death. 

In our case series, the baseline ESR values, the median ferritin, LDH and total bilirubin levels of the non-survivors were higher than those of the survivors. But, due to limited numbers of patients to conclude statistical significance with parametric and non-parametric tests, we do not give any hypothetical test results here. We may say that more tissue destruction like liver as cholestatic hepatitis and blood cells hemolysis can explain the higher LDH and total bilirubin levels in non-survivors as bad prognostic factors.

Table 2. Underlying Diseases, PET/CT Involvement, Treatments and Outcomes of Hemophagocytic Lymphohistiocytosis Patients.

| Patient | Secondary disease | Ferritin levels (µg/L) | Triglycerides (mg/dL) | PET/CT involvement area | First treatment | Secondary treatment | Adjunctive treatment | Outcome |
|---------|-------------------|------------------------|-----------------------|-------------------------|----------------|---------------------|---------------------|---------|
| 1       | DLBCL             | 1381                   | 480                   | BM, Spleen, LN          | VP-16 + DEX + CyA | R-CHOP              | Alive               |         |
| 2       | Idiopathic        | 7300                   | 468                   | BM, Spleen, Liver, LN   | VP-16 + DEX + CyA | Alive               | Alive               |         |
| 3       | DLBCL             | 78286                  | 528                   | BM, Spleen, LN          | VP-16 + DEX     | Alive               |         |
| 4       | EBV               | 90000                  | 1170                  | BM, Liver               | DEX + IVIG     | CyA                 |         |
| 5       | CMV               | 100000                 | 589                   | NA                      | mPSL           | GCV                 | Died                |         |
| 6       | SLE               | 1230                   | 245                   | NA                      | mPSL + IVIG    | Rituximab           | Died                |         |
| 7       | Idiopathic        | 909                    | 259                   | NA                      | mPSL + IVIG    | Alive               |         |
| 8       | RA                | 1656                   | NA                    | mPSL                    | IVIG           | mPSL + CyA          | Alive               |         |
| 9       | Idiopathic        | 1010                   | NA                    | mPSL + CyA              | Alive          |         |
| 10      | Ulcerative colitis| 15100                  | 789                   | NA                      | mPSL + IVIG    | Alive               |         |
| 11      | Influenza         | 21191                  | 281                   | NA                      | mPSL + IVIG    | Oselamivir          | Alive               |         |
| 12      | Idiopathic        | 10027                  | 501                   | NA                      | mPSL + IVIG    | Died                |         |
| 13      | Toxoplasmosis     | 34000                  | 1206                  | BM, Spleen, Liver, LN   | mPSL + IVIG    | TMP/SMZ             | Died                |         |
| 14      | CCHF              | 1405                   | 921                   | BM, Spleen, Liver       | mPSL           | Alive               |         |
| 15      | Histoplasmosis    | 2500                   | 921                   | BM, Spleen              | mPSL           | Itraconazole        | Died                |         |
| 16      | EBV               | 7029                   | 525                   | NA                      | VP-16 + DEX + CyA | Died                |         |
| 17      | EBV               | 88967                  | 654                   | NA                      | VP-16 + DEX + CyA | Died                |         |
| 18      | Idiopathic        | 27386                  | 103                   | NA                      | VP-16 + DEX + CyA | Died                |         |
| 19      | EBV               | 10500                  | 417                   | NA                      | DEX + IVIG     | Acyclovir           | Died                |         |
| 20      | Idiopathic        | 85024                  | 266                   | NA                      | VP-16 + DEX     | Died                |         |
| 21      | Idiopathic        | 8826                   | 374                   | NA                      | VP-16 + DEX + CyA | Died                |         |
| 22      | Still’s disease   | 2551                   | 232                   | NA                      | mPSL + IVIG    | Alive               |         |
| 23      | Idiopathic        | 15000                  | 43                    | NA                      | IVIG           | Alive               |         |
| 24      | Intravascular DLBCL| 562                   | 416                   | BM, Spleen, Lung        | R-CHOP         | ASCT                | Alive               |         |
| 25      | Idiopathic        | 639                    | 561                   | BM, Spleen, Liver       | mPSL + CyA     | Alive               |         |
| 26      | Idiopathic        | 9650                   | 165                   | Spleen, liver           | mPSL + IVIG    | Alive               |         |

NA: not available; BM: bone marrow; LN: lymph node; mPSL: methylprednisolone; DEX: dexamethasone; CyA: cyclosporine; DLBCL: diffuse large B-cell lymphoma; IVIG: intravenous immunoglobulins; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; AOSD: adult-onset Still’s disease; VP-16: etoposide; GCV: ganciclovir; R-CHOP: rituximab, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], and prednisone; GCSF, granulocyte colony-stimulating factor; TMP/SMX, trimethoprim-sulfamethoxazole; CCHF, Crimean-Congo hemorrhagic fever. ASCT: Autologous Hematopoietic Stem Cell Transplantation.
Hemophagocytosis has been demonstrated in HLH patients, especially in the bone marrow, spleen, liver, and lymph nodes. It is a diagnostic criterion. Hemophagocytosis was reported in bone marrow aspirates in 84% of HLH cases of the literature, which is similar to our findings. Hemophagocytosis by itself is not a pathognomonic finding for the diagnosis of HLH.\textsuperscript{15} Because hemophagocytosis may be a late finding in progressive HLH, repeat biopsies may be needed to confirm the diagnosis in some cases.\textsuperscript{1}

PET/CT is a recently developed technique that is especially useful in cases of malignancy, and this method may be valuable for diagnosing underlying malignancies versus isolated HLH. In several reported cases, the diffuse involvement of the bone marrow associated with spleen, liver, and lymph node involvement has been found on PET/CT scans, which is consistent with hemophagocytosis.\textsuperscript{16} Little information is available regarding whether PET/CT findings were related to underlying or opportunistic diseases versus HLH. The underlying conditions of our patients may have been responsible for the PET/CT findings; however, one idiopathic case showed a diffuse involvement of the reticuloendothelial system, which was considered to be associated with HLH (Figure 1).

In 2004, a new HLH treatment protocol was published (HLH-2004).\textsuperscript{7} Corticosteroids, cyclosporine, and etoposide constitute the backbone of treatment. Among our cases, only two patients were treated with this backbone therapy, and they recovered completely with good prognoses. Etoposide-based steroid combination regimens have been confirmed to improve HLH-associated outcomes in most trials.\textsuperscript{17}

All the patients had been treated with at least one antibiotic regimen preceding the diagnosis of suspected sepsis (data not presented). Of the 25 patients, 3 received only high-dose corticosteroids as initial management, and only 1 case (a CCHF patient) resolved clinically. All the patients with rheumatologic disease-related HLH responded to treatment with good prognoses. While etoposide and cyclosporine combination with high dose corticosteroid is the recommended regime for HLH, in our study, eight patients were treated with etoposide containing regimes, and six of them died. Mortality in rheumatological diseases is significantly lower than that in infection- or malignancy-related HLH.\textsuperscript{18}

The reported mortality of secondary HLH in adult case series varies from 20-74.8%, which is similar to the rate of 44% in our case series.\textsuperscript{4,11} Our cases with underlying rheumatological diseases also showed a good prognosis.

Advanced age, the presence of lymphoma or infectious disease, transplantation, and persistent fever within three days after the first treatment have been clinically defined as poor prognostic factors.\textsuperscript{4} Although a statistical comparison was not possible, ten of the fatal cases in this study had an infectious (~50%) and idiopathic (~50%) etiology.

This retrospective case series study was intended to present an additional adult HLH case series to the literature. Its retrospective nature and small sample size are important limitations. In conclusion, HLH occurs secondary to many diseases observed in internal medicine practice. When a long-lasting fever is complicated by bicytopenia or pancytopenia (especially), clinicians must promptly consider the possibility of HLH syndrome since early diagnosis improves...
patients’ prognosis. "In our case series, the baseline ESR values, the median ferritin, LDH and total bilirubin levels of the non-survivors were higher than those of the survivors.

References:

1. Rosado FGN, Kim AS: Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol 2013; 139:713–727. https://doi.org/10.1093/ajcp/ZDKJ4ICOUAT PMid:23690113

2. Basheer A, Padhi S, Boopathy V, Mallick S, Nair S, Varghese RG, Kanungo R. Hemophagocytic Lymphohistiocytosis: An Unusual Complication of Orientia tsutsugamushi Disease (Scrub Typhus). Mediterr J Hematol Infect Dis. 2015; 7(1):e20151008. https://doi.org/10.4084/MJHID.2015.008. eCollection 2015.

3. Hayden A, Park S, Giustini D, et al.: Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic review. Blood Rev 2016; 30:411–420. https://doi.org/10.1016/j.blre.2016.05.001 PMid:27238576

4. Rivière S, Galcier L, Coppel P, et al.: Reactive hemophagocytic syndrome in adults: A multicenter retrospective analysis of 162 patients. Am J Med 2014. https://doi.org/10.1016/j.amjmed.2014.04.034 PMid:24835040

5. Wormsbecker AJ, Sweet DD, Mann SL, et al.: Conditions associated with extreme hyperferritinemia (>3000 μg/L) in adults. Intern Med J 2015; 45:828–833. https://doi.org/10.1111/imj.12768 PMid:25851400

6. Trottéastam H, Horne A, Aricò M, et al.: Chemomunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011; 118:4577–4584. https://doi.org/10.1182/blood-2011-06-356261 PMid:21900192 PMCid:PMC3208276

7. Henter J-I, Horne A, Aricò M, et al.: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124–131. https://doi.org/10.1002/hlc.21039 PMid:16937360

8. Dick R, Watkinson A: The liver and spleen. Textb Radiol Imaging 2002; 981–1028

9. Song Y, Pei R-J, Wang Y-N, et al.: Central Nervous System Involvement in Hemophagocytic Lymphohistiocytosis in Adults: A Retrospective Analysis of 96 Patients in a Single Center. Chin Med J (Engl) 2018; 131:776–783. https://doi.org/10.4103/0366-6999.228234 PMid:29578120 PMCid:PMC5887735

10. Lorenz F, Klímková M, Pawłowicz E, et al.: Clinical characteristics, therapy response, and outcome of 51 adult patients with hematological malignancy-associated hemophagocytic lymphohistiocytosis: a single institution experience. Leuk Lymphoma 2018; 1–11. https://doi.org/10.1080/10428194.2017.1403018

11. Rames-Casals M, Brito-Zerón P, López-Guillermo A, et al.: Adult haemophagocytic syndrome. Lancet 2014; 383:1503–1516. https://doi.org/10.1016/S0140-6736(13)61048-X

12. Ozen S, Dai A, Coskun E, Oztuzcu S, Ergun S, Aktekin E, Yavuz S, Bay A. Importance of hyperbilirubinemia in differentiation of primary and secondary hemophagocytic lymphohistiocytosis in pediatric cases. Mediterr J Hematol Infect Dis. 2014;6:e2014067. doi: 10.4084/MJHID.2014.067. eCollection 2014

13. Sackett K, Cunderlik M, Sahn N, et al.: Extreme Hyperferritinaemia: Causes and Impact on Diagnostic Reasoning. Am J Clin Pathol 2016; 145:646–650. https://doi.org/10.1093/ajcp/aqw053 PMid:27247369

14. François B, Trimoreau F, Desachy A, et al.: [Hemophagocytosis during multiple organ failure: M-CSF overproduction or viral reactivation?]. Ann Fr Anesthésie Réanimation 2001; 20:514–519. https://doi.org/10.1016/S0750-4749(01)70166-4

15. Ho C, Yao X, Tian L, et al.: Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol 2014; 141:62–71. https://doi.org/10.1016/S0735-7658(14)60410-5

16. Kim J, Yoo SW, Kang S-R, et al.: Clinical implication of F-18 FDG PET/CT in patients with secondary hemophagocytic lymphohistiocytosis. Ann Hematol 2014; 93:661–666. https://doi.org/10.1007/s00277-014-2467-2

17. Bergsten E, Horne A, Aricò M, et al.; Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 2017; 130:2728–2738. https://doi.org/10.1182/blood-2017-06-783439 PMid:28953695 PMCid:PMC5785801

18. Ishii E, Ohga S, Imashuku S, et al.: Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007; 86:58–65. https://doi.org/10.1016/j.ijh.2007.07.012 PMid:17675268